{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:24:38Z","timestamp":1790126678988,"version":"4.0.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,15]]},"abstract":"<jats:p>In immunotherapy, dendritic cells (DCs) can be used as powerful antigen-presenting cells to enhance or suppress antigen-specific immunity upon in vivo transfer in mice or humans. However, to generate sufficient numbers of DCs, most protocols include an ex vivo culture step, wherein the cells are exposed to heterologous serum and\/or antigenic stimuli. In mouse models of virus infection and virus-induced autoimmunity, we tested how heterologous serum affects the immunomodulatory capacity of immature DCs generated in the presence of IL-10 by comparing fetal bovine serum (FBS)- or normal mouse serum (NMS)-supplemented DC cultures. We show that FBS-exposed DCs induce a systemic immune deviation characterized by reduction of virus-specific T cells, delayed viral clearance, and enhanced systemic production of interleukin 4 (IL-4), IL-5, and IL-10 to FBS-derived antigens, including bovine serum albumin (BSA). By contrast, DCs generated in NMS-supplemented cultures modulated immunity and autoimmunity in an antigen-specific fashion. These cells did not induce systemic IL-4, IL-5, or IL-10 production and inhibited generation of virus-specific T cells or autoimmunity only if pulsed with a viral antigen. These data underscore the importance of using autologous serum-derived immature DCs in preclinical animal studies to accurately assess their immunomodulatory potential in future human therapeutic settings, where application of FBS is not feasible.<\/jats:p>","DOI":"10.1182\/blood-2005-03-0975","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T02:53:26Z","timestamp":1124852006000},"page":"4225-4233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo"],"prefix":"10.1182","volume":"106","author":[{"given":"Claus","family":"Haase","sequence":"first","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Ejrnaes","sequence":"additional","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Juedes","sequence":"additional","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wolfe","sequence":"additional","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Markholst","sequence":"additional","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"von Herrath","sequence":"additional","affiliation":[{"name":"From the Hagedorn Research Institute, Gentofte, Denmark; the La Jolla Institute for Allergy and Immunology, San Diego, CA; and Novo Nordisk, ImmunoPharmacology, Ma\u030al\u00f8v, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111818293516600_REF1","doi-asserted-by":"crossref","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392: 245-252.","DOI":"10.1038\/32588"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23: 445-449.","DOI":"10.1016\/S1471-4906(02)02281-0"},{"key":"2019111818293516600_REF3","doi-asserted-by":"crossref","unstructured":"Steinman RM, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2003;987: 15-25.","DOI":"10.1111\/j.1749-6632.2003.tb06029.x"},{"key":"2019111818293516600_REF4","doi-asserted-by":"crossref","unstructured":"Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev. 2003;196: 125-146.","DOI":"10.1046\/j.1600-065X.2003.00079.x"},{"key":"2019111818293516600_REF5","doi-asserted-by":"crossref","unstructured":"Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens invitro can prime antigen-specific MHC-restricted T cell in-situ. J Exp Med. 1990;172: 631-640.","DOI":"10.1084\/jem.172.2.631"},{"key":"2019111818293516600_REF6","doi-asserted-by":"crossref","unstructured":"Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor. J Exp Med. 1992;176: 1693-1702.","DOI":"10.1084\/jem.176.6.1693"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods. 1996;196: 137-151.","DOI":"10.1016\/0022-1759(96)00078-6"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196: 121-135.","DOI":"10.1016\/0022-1759(96)00079-8"},{"key":"2019111818293516600_REF9","doi-asserted-by":"crossref","unstructured":"Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223: 77-92.","DOI":"10.1016\/S0022-1759(98)00204-X"},{"key":"2019111818293516600_REF10","doi-asserted-by":"crossref","unstructured":"Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med. 1993;178: 479-488.","DOI":"10.1084\/jem.178.2.479"},{"key":"2019111818293516600_REF11","doi-asserted-by":"crossref","unstructured":"Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182: 389-400.","DOI":"10.1084\/jem.182.2.389"},{"key":"2019111818293516600_REF12","doi-asserted-by":"crossref","unstructured":"MacDonald AS, Pearce EJ. Cutting edge: polarized Th cell response induction by transferred antigen-pulsed dendritic cells is dependent on IL-4 or IL-12 production by recipient cells. J Immunol. 2002;168: 3127-3130.","DOI":"10.4049\/jimmunol.168.7.3127"},{"key":"2019111818293516600_REF13","doi-asserted-by":"crossref","unstructured":"Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol. 1996;156: 2918-2926.","DOI":"10.4049\/jimmunol.156.8.2918"},{"key":"2019111818293516600_REF14","doi-asserted-by":"crossref","unstructured":"Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med. 1998;188: 1493-1501.","DOI":"10.1084\/jem.188.8.1493"},{"key":"2019111818293516600_REF15","doi-asserted-by":"crossref","unstructured":"Papaccio G, Nicoletti F, Pisanti FA, Bendtzen K, Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology. 2000;141: 1500-1505.","DOI":"10.1210\/endo.141.4.7437"},{"key":"2019111818293516600_REF16","doi-asserted-by":"crossref","unstructured":"Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol. 2002;32: 2021-2030.","DOI":"10.1002\/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J"},{"key":"2019111818293516600_REF17","doi-asserted-by":"crossref","unstructured":"Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes. 1999;48: 2300-2308.","DOI":"10.2337\/diabetes.48.12.2300"},{"key":"2019111818293516600_REF18","doi-asserted-by":"crossref","unstructured":"Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol. 2000;30: 1813-1822.","DOI":"10.1002\/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8"},{"key":"2019111818293516600_REF19","doi-asserted-by":"crossref","unstructured":"Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99: 351-358.","DOI":"10.1073\/pnas.231606698"},{"key":"2019111818293516600_REF20","doi-asserted-by":"crossref","unstructured":"Steinman RM. The control of immunity and tolerance by dendritic cells. Pathologie Biologie (Paris). 2003;51: 59-60.","DOI":"10.1016\/S0369-8114(03)00096-8"},{"key":"2019111818293516600_REF21","doi-asserted-by":"crossref","unstructured":"Moore KW, Malefyt RD, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19: 683-765.","DOI":"10.1146\/annurev.immunol.19.1.683"},{"key":"2019111818293516600_REF22","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193: 233-238.","DOI":"10.1084\/jem.193.2.233"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood. 1999;93: 1634-1642.","DOI":"10.1182\/blood.V93.5.1634"},{"key":"2019111818293516600_REF24","doi-asserted-by":"crossref","unstructured":"Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159: 4772-4780.","DOI":"10.4049\/jimmunol.159.10.4772"},{"key":"2019111818293516600_REF25","doi-asserted-by":"crossref","unstructured":"Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest. 1999;104: 189-194.","DOI":"10.1172\/JCI7209"},{"key":"2019111818293516600_REF26","doi-asserted-by":"crossref","unstructured":"Broberg EK, Salmi AA, Hukkanen V. IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB\/c experimental autoimmune encephalomyelitis. Neurosci Lett. 2004;364: 173-178.","DOI":"10.1016\/j.neulet.2004.04.059"},{"key":"2019111818293516600_REF27","doi-asserted-by":"crossref","unstructured":"Ohashi PS, Oehen S, Buerki K, et al. Ablation of `tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991;65: 305-317.","DOI":"10.1016\/0092-8674(91)90164-T"},{"key":"2019111818293516600_REF28","doi-asserted-by":"crossref","unstructured":"Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell. 1991;65: 319-331.","DOI":"10.1016\/0092-8674(91)90165-U"},{"key":"2019111818293516600_REF29","doi-asserted-by":"crossref","unstructured":"von Herrath MG, Dockter J, Oldstone MB. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity. 1994;1: 231-242.","DOI":"10.1016\/1074-7613(94)90101-5"},{"key":"2019111818293516600_REF30","doi-asserted-by":"crossref","unstructured":"Dutko FJ, Oldstone MBA. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol. 1983;64: 1689-1698.","DOI":"10.1099\/0022-1317-64-8-1689"},{"key":"2019111818293516600_REF31","doi-asserted-by":"crossref","unstructured":"Haase C, Jorgensen TN, Michelsen BK. Both exogenous and endogenous interleukin-10 affects the maturation of bone-marrow-derived dendritic cells in vitro and strongly influences T-cell priming in vivo. Immunology. 2002;107: 489-499.","DOI":"10.1046\/j.1365-2567.2002.01529.x"},{"key":"2019111818293516600_REF32","doi-asserted-by":"crossref","unstructured":"Muller G, Muller A, Jonuleit H, et al. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches. J Invest Dermatol. 2000;114: 142-148.","DOI":"10.1046\/j.1523-1747.2000.00832.x"},{"key":"2019111818293516600_REF33","doi-asserted-by":"crossref","unstructured":"Garboczi DN, Utz U, Ghosh P, et al. Assembly, specific binding, and crystallization of a human TCR-\u03b1\u03b2 with an antigenic Tax peptide from human T lymphotropic virus type 1 and the class I MHC molecule HLA-A2. J Immunol. 1996;157: 5403-5410.","DOI":"10.4049\/jimmunol.157.12.5403"},{"key":"2019111818293516600_REF34","doi-asserted-by":"crossref","unstructured":"Christen U, Benke D, Wolfe T, et al. Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest. 2004;113: 74-84.","DOI":"10.1172\/JCI17005"},{"key":"2019111818293516600_REF35","doi-asserted-by":"crossref","unstructured":"Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182: 255-260.","DOI":"10.1084\/jem.182.1.255"},{"key":"2019111818293516600_REF36","doi-asserted-by":"crossref","unstructured":"Maldonado-Lopez R, De Smedt T, Michel P, et al. CD8\u03b1+ and CD8\u03b1- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 1999;189: 587-592.","DOI":"10.1084\/jem.189.3.587"},{"key":"2019111818293516600_REF37","doi-asserted-by":"crossref","unstructured":"Maldonado-Lopez R, De Smedt T, Michel P, et al. CD8\u03b1+ and CD8\u03b1- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 1999;189: 587-592.","DOI":"10.1084\/jem.189.3.587"},{"key":"2019111818293516600_REF38","doi-asserted-by":"crossref","unstructured":"Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-\u03b1\u03b2 transgenic model. J Exp Med. 1995;182: 1579-1584.","DOI":"10.1084\/jem.182.5.1579"},{"key":"2019111818293516600_REF39","doi-asserted-by":"crossref","unstructured":"Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med. 1995;182: 1591-1596.","DOI":"10.1084\/jem.182.5.1591"},{"key":"2019111818293516600_REF40","doi-asserted-by":"crossref","unstructured":"Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J Exp Med. 1997;186: 239-245.","DOI":"10.1084\/jem.186.2.239"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Belz GT, Behrens GMN, Smith CM, et al. The CD8\u03b1+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med. 2002;196: 1099-1104.","DOI":"10.1084\/jem.20020861"},{"key":"2019111818293516600_REF42","doi-asserted-by":"crossref","unstructured":"Probst HC, Lagnel J, Kollias G, van den Brock. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 2003;18: 713-720.","DOI":"10.1016\/S1074-7613(03)00120-1"},{"key":"2019111818293516600_REF43","doi-asserted-by":"crossref","unstructured":"Kristensen NN, Madsen AN, Thomsen AR, Christensen JP. Cytokine production by virus-specific CD8+ T cells varies with activation state and localization, but not with TCR avidity. J Gen Virol. 2004;85: 1703-1712.","DOI":"10.1099\/vir.0.79903-0"},{"key":"2019111818293516600_REF44","doi-asserted-by":"crossref","unstructured":"Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell, IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170: 2081-2095.","DOI":"10.1084\/jem.170.6.2081"},{"key":"2019111818293516600_REF45","doi-asserted-by":"crossref","unstructured":"Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 1994;12: 635-673.","DOI":"10.1146\/annurev.iy.12.040194.003223"},{"key":"2019111818293516600_REF46","doi-asserted-by":"crossref","unstructured":"Alpan O, Bachelder E, Isil E, Arnheiter H, Matzinger P. `Educated' dendritic cells act as messengers from memory to naive T helper cells. Nat Immunol. 2004;5: 615-622.","DOI":"10.1038\/ni1077"},{"key":"2019111818293516600_REF47","doi-asserted-by":"crossref","unstructured":"von Herrath MG, Coon B, Lewicki H, Mazarguil H, Gairin JE, Oldstone MBA. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes. J Immunol. 1998;161: 5087-5096.","DOI":"10.4049\/jimmunol.161.9.5087"},{"key":"2019111818293516600_REF48","doi-asserted-by":"crossref","unstructured":"von Herrath MG, Dyrberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest. 1996;98: 1324-1331.","DOI":"10.1172\/JCI118919"},{"key":"2019111818293516600_","doi-asserted-by":"crossref","unstructured":"Pajak B, et al. Role of CDalpha+ and CDalpha-dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol. 1999;66: 242-246.","DOI":"10.1002\/jlb.66.2.242"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4225\/464998\/zh802405004225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4225\/464998\/zh802405004225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T08:12:09Z","timestamp":1683187929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/13\/4225\/133238\/Immunomodulatory-dendritic-cells-require"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":49,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2005,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-0975","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]}}}